Medivation Announces Participation at Upcoming Investor Conferences
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 05/11/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences:
David Hung, M.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Health Care Conference on Wednesday, May 16 at 4:20p.m. Pacific Time in Las Vegas, NV.
Patrick Machado, chief business and financial officer, will present at Jefferies 2012 Global Healthcare Conference on Tuesday, June 5 at 3:00p.m. Eastern Time in New York, NY.
Patrick Machado, chief business and financial officer, will present at the William Blair Growth Stock Conference on Wednesday, June 13 at 11:00a.m. Central Time in Chicago, IL.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide in Phase 3 development to treat advanced prostate cancer and in Phase 1 development to treat breast cancer. For more information, please visit us at .
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2012 - 20:30 Uhr
Sprache: Deutsch
News-ID 145693
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 281 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
